From the BlogSubscribe Now

Archives for June 2017

Indi Molecular Building Discovery Platform With Fresh Series A Financing

360Dx / GenomeWeb (June 30, 2017)
[Read more…]

Indi Molecular Raises $11.5 in Series A Round

BioCentury (June 29, 2017)
[Read more…]

Indi Molecular raises $11.5M in series A to back new synthetic class in research, imaging

BioWorld Medtech (June 29, 2017)
[Read more…]

Indi Molecular Raises $11.5M Series A to Accelerate PCC Platform Development

CULVER CITY, CA – June 28, 2017 – Indi Molecular, an emerging life sciences company that is developing a novel, synthetic class of binders with antibody-like properties called protein catalyzed capture agents (PCCs), announced today that it has raised a $11.5 million Series-A financing led by M Ventures (Merck Ventures BV, Amsterdam, the Netherlands, a subsidiary of Merck KGaA, Darmstadt Germany known as M Ventures in the United States and Canada), the strategic corporate venture capital arm of Merck KGaA Darmstadt, Germany; Legend Capital, a venture capital/private equity fund based in Beijing; Sabey Corporation; and existing investors including Asset Management Ventures. As part of the financing, Dr. Andreas Jurgeit from Merck Ventures and Dr. Darren Cai from Legend Capital will join Indi Molecular’s board. The Series-A proceeds will be used to establish a high throughput PCC discovery platform and to advance existing leads in PET immuno-oncology imaging to clinical stage.
[Read more…]